Author

A. Abayasingam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

R. A. Bull· 2 shared A. Adhikari· 1 shared A. G. Stewart· 1 shared A. Kelleher· 1 shared A. R. Lloyd· 1 shared A. W. Bartlett· 1 shared B. Grubor-Bauk· 1 shared B. Hudson· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

R. A. Bull

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection.

A. Adhikari, A. Abayasingam, C. Rodrigo, D. Agapiou, E. Pandzic, N. A. Brasher, B. S. M. Fernando, E. Keoshkerian, H. Li, H. N. Kim, M. Lord, G. Popovic, W. Rawlinson, M. Mina, J. J. Post, , N. Tedla

This study shows that phagocytic and neutralisation functions of anti-Spike antibodies persist in SARS-CoV-2 convalescents despite declining antibody titers, with improved antibody affinity correlating with maintained effector functions.

bioRxiv · Dec 21, 2021 · PreprintImmunology

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies

R. Rouet, O. Mazigi, G. J. Walker, D. B. Langley, M. Sobti, P. Schofield, H. Lenthall, J. Jackson, S. Ubiparipovic, J. Y. Henry, A. Abayasingam, D. Burnett, A. Kelleher, R. Brink, R. A. Bull, , D. Christ

This paper explores antibody maturation strategies to enhance the neutralization of SARS-CoV-2 using SARS-CoV-1 antibodies, finding that some variants show potent neutralization with IC50 of 160 ng/ml.

bioRxiv · Dec 14, 2020Immunology